دورية أكاديمية
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
| العنوان: | Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis |
|---|---|
| المؤلفون: | Borghaei, Hossein, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Pluzanski, Adam, Bernabé Caro, Reyes, Gutierrez, Martin E., Ohe, Yuichiro, Nishio, Makoto, Goldman, Jacki P., Ready, Neal, Spigel, David R., Ramalingam, Suresh S., Paz-Ares, Luis, Gainor, Justin F., Ahmed, Samreen, Reck, Martin, Maio, Michele, O'Byrne, Kenneth J., Memaj, Arteid, Nathan, Faith Ellen, Tran, Phuong, Hellmann, Matthew D., Brahmer, Julie R. |
| المساهمون: | Bristol Myers Squibb Foundation, Ono Pharmaceutical |
| بيانات النشر: | Elsevier European Society for Medical Oncology |
| سنة النشر: | 2023 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | NSCLC, Dual immunotherapy, Nivolumab, Ipilimumab |
| الوصف: | © 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0Test/). ; [Background] First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. ; [Patients and methods] Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. ; [Results] In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%, ≥1%, 1%-49%, or ≥50%, 3-year OS rates were 30%, 38%, 30%, and 48%. Three-year OS rates were 30% and 38% in patients with squamous or non-squamous histology. Efficacy outcomes in patients aged ≥75 years were similar to the overall pooled population (median OS, 20.1 months; 3-year OS rate, 34%). In the pooled population, responders to nivolumab plus ipilimumab at 6 months had longer post-landmark OS than those with stable or progressive disease; 3-year OS rates were 66%, 22%, and 14%, respectively. Greater depth of response was associated with prolonged survival; in patients with tumor burden reduction ≥80%, 50% to <80%, or 30% to <50%, 3-year OS rates were 85%, 72%, and 44%, ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0923-7534 |
| العلاقة: | Publisher's version; The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1016/j.annonc.2022.11.006Test; https://doi.org/10.1016/j.annonc.2022.11.006Test; Sí; Annals of Oncology 34(2): 173-185 (2023); http://hdl.handle.net/10261/351369Test |
| DOI: | 10.1016/j.annonc.2022.11.006 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2022.11.006Test http://hdl.handle.net/10261/351369Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.870871E |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.11.006 |